EMAIL THIS PAGE TO A FRIEND

BioMed research international

An in vivo microdialysis study of FLZ penetration through the blood-brain barrier in normal and 6-hydroxydopamine induced Parkinson's disease model rats.


PMID 25045708

Abstract

FLZ (N-[2-(4-hydroxy-phenyl)-ethyl]-2-(2,5-dimethoxy-phenyl)-3-(3-methoxy-4-hydroxy-phenyl)-acrylamide) is a novel synthetic squamosamide derivative and a potential anti-Parkinson's disease (PD) agent. The objective of the present study was to investigate the penetration of free FLZ across the BBB and the effects of P-gp inhibition on FLZ transport in normal and 6-hydroxydopamine (6-OHDA) induced PD model rats. In vivo microdialysis was used to collect FLZ containing brain and blood dialysates following intravenous (i.v.) drug administration either with or without pretreatment with the specific P-gp inhibitor, zosuquidar trihydrochloride (zosuquidar·3HCl). A sensitive, rapid, and reliable ultraperformance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) technique was developed and validated to quantitate free FLZ levels in the dialysates. No significant differences were observed in the brain/blood FLZ area under the concentration-time curve (AUC) ratio between normal and PD model rats. However, pretreatment with zosuquidar·3HCl markedly increased the AUC ratio in both rat models. In addition, FLZ penetration was similar in zosuquidar·3HCl-pretreated normal and PD rats. These results suggest that P-gp inhibition increases BBB permeability to FLZ, thereby supporting the hypothesis that P-gp normally restricts FLZ transfer to the brain. These findings could provide reference data for future clinical trials and may aid investigation of the BBB permeability of other CNS-active substances.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

H8523
6-Hydroxydopamine hydrobromide, ≥90% (HPLC), solid
C8H11NO3 · HBr
H116
6-Hydroxydopamine hydrobromide, contains ascorbic acid as stabilizer, ≥98% (HPLC)
C8H11NO3 · HBr
162957
6-Hydroxydopamine hydrobromide, 95%
C8H11NO3 · HBr
45983
Acetonitrile, analytical standard
C2H3N
PHR1551
Acetonitrile, Pharmaceutical Secondary Standard; Certified Reference Material
C2H3N
00712
Acetonitrile solution, ~20% in H2O, for protein sequence analysis
C2H3N
A1300000
Ascorbic acid, European Pharmacopoeia (EP) Reference Standard
C6H8O6
1043003
Ascorbic acid, United States Pharmacopeia (USP) Reference Standard
C6H8O6
PHR1008
Ascorbic Acid
C6H8O6
57803
L-Ascorbic acid, certified reference material, TraceCERT®
C6H8O6
95212
L-Ascorbic acid, tested according to Ph.Eur.
C6H8O6
47863
L-Ascorbic acid, analytical standard
C6H8O6
PHR1320
Residual Solvent - Acetonitrile, Pharmaceutical Secondary Standard; Certified Reference Material
C2H3N
1601340
Residual Solvent Class 2 - Acetonitrile, United States Pharmacopeia (USP) Reference Standard
C2H3N
71383
Sodium chloride, tested according to Ph.Eur.
ClNa
71387
Sodium chloride, certified reference material for titrimetry, certified by BAM, according to ISO 17025, ≥99.5%
ClNa
PHR1321
Sodium chloride, Pharmaceutical Secondary Standard; Certified Reference Material
ClNa
71177
Sodium standard for AAS, ready-to-use, traceable to BAM, in H2O
ClNa